Understanding how stress affects retinal cell survival to prevent vision loss
Transcriptional control of stress-induced resistance to retinal degeneration
This study is looking at how a protein called STAT3 helps protect the light-sensitive cells in your eyes from damage, which could lead to new ways to prevent vision loss from conditions like age-related macular degeneration.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10904915 on NIH RePORTER |
What this research studies
This research investigates the mechanisms that lead to the death of photoreceptor cells in the retina, which is a major cause of vision loss in conditions like age-related macular degeneration. By focusing on a protein called STAT3, the study aims to uncover how it helps retinal cells resist damage and survive under stress. Using advanced techniques like single-cell RNA sequencing and ChIP sequencing, researchers will identify the genes and networks involved in this protective response. This could lead to new strategies for preventing blindness from various retinal degenerations.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk of or diagnosed with retinal degenerative diseases, particularly age-related macular degeneration.
Not a fit: Patients with retinal degeneration caused by genetic mutations that are not influenced by the mechanisms studied may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that protect retinal cells and preserve vision in patients with retinal degenerative diseases.
How similar studies have performed: Previous research has shown promise in targeting similar protective mechanisms in retinal cells, suggesting that this approach could be effective.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Ash, John D — University of Pittsburgh at Pittsburgh
- Study coordinator: Ash, John D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.